References
- Diabetes Control and Complications Trial Research Group; Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Eng J Med. 1993;329(14):977–986.
- King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol. 1999;48(5):643–648.
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet. 1998;352(9131):837–853.
- American Diabetes Association. 6. Glycaemic targets: standards of medical care in diabetes—2020. Diabetes Care. 2020;43(Supplement 1):S66–S76.
- Kalra S, Mukherjee J, Ramachandran A, et al. Hypoglycemia: the neglected complication. Indian J Endocrinol Metab. 2013;17(5):819–834.
- Abdelhafiz A, Rodríguez-Mañas L, Morley J, et al. Hypoglycaemia in older people - a less well recognised risk factor for frailty. Aging Dis. 2015;6(2):156.
- International Hypoglycaemia Study Group. Minimizing hypoglycaemia in diabetes. Diabetes Care. 2015;38(8):1583–1591.
- Bremer J, Jauch-Chara K, Hallschmid M, et al. Hypoglycaemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care. 2009;32(8):1513–1517.
- Chow E, Bernjak A, Williams S, et al. Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. Diabetes. 2014;63(5):1738–1747.
- Secrest A, Becker D, Kelsey S, et al. Characterizing sudden death and dead-in-bed syndrome in type 1 diabetes: analysis from two childhood-onset type 1 diabetes registries. Diab Med. 2011;28(3):293–300.
- Longo R, Sperling S. Personal versus professional continuous glucose monitoring: when to use which on whom. Diabetes Spectr. 2019;32(3):183–193.
- Bergenstal R, Kerr M, Roberts G, et al. Flash CGM is associated with reduced diabetes events and hospitalizations in insulin-treated type 2 diabetes. J Endocr Soc. 2021;5(4):bvab013.
- Sola D, Rossi L, Schianca G, et al. State of the art paper sulfonylureas and their use in clinical practice. aoms. 2015;4:840–848.
- Zhu L, Ang L, Tan W, et al. A study to evaluate the prevalence of impaired awareness of hypoglycaemia in adults with type 2 diabetes in outpatient clinic in a tertiary care centre in Singapore. Ther Adv Endocrinol. 2017;8(5):69–74.
- Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. New Eng J Med. 2008;358(24):2545–2559.
- Haak T, Hanaire H, Ajjan R, et al. Use of flash Glucose-Sensing technology for 12 months as a replacement for blood glucose monitoring in insulin-treated type 2 diabetes. Diabetes Ther. 2017;8(3):573–586.
- Frier BM, Schernthaner G, Heller SR. Hypoglycaemia and cardiovascular risks. Diabetes Care. 2011;34(Supplement_2):S132–S137.
- Robinson RTCE, Harris ND, Ireland RH, et al. Mechanisms of abnormal cardiac repolarization during Insulin-Induced hypoglycaemia. Diabetes. 2003;52(6):1469–1474.
- Lipska KJ, Warton EM, Huang ES, et al. HbA1c and risk of severe hypoglycaemia in type 2 diabetes: the diabetes and aging study. Diabetes Care. 2013;36(11):3535–3542.